Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity

Tissue Antigens

Volumn 78, Issue 1, 2011, Pages 11-20

  Kostenko, Lyudmila ^a   Kjer Nielsen, L ^a   Nicholson, I ^b   Hudson, F ^b   Lucas, A ^c   Foley, B ^c   Chen, K ^d   Lynch, K ^d   Nguyen, J ^d   Wu, A H B ^d   Tait, B D ^b   Holdsworth, R ^b   Mallal, S ^c   Rossjohn, J ^e   Bharadwaj, M ^a   McCluskey, James ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Drug hypersensitivity; Human leukocyte antigen; Mean fluorescence intensity; Monoclonal antibody; Peripheral blood mononuclear cells

Indexed keywords

ABACAVIR; HLA ANTIBODY; HLA B ANTIGEN; HLA B5701 ANTIGEN; HLA B5801 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E12; UNCLASSIFIED DRUG;

ALLOTYPE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; BLOOD STAIN; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG PURIFICATION; EPITOPE MAPPING; FLOW CYTOMETRY; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOASSAY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CELLS, CULTURED; DRUG HYPERSENSITIVITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY TESTING; HLA-B ANTIGENS; HUMANS; MASS SCREENING; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; TIME FACTORS;

EID: 79958694904     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2011.01649.x     Document Type: Article

References (27)

1. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005: 102: 4134-9.
2. Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008: 18: 99-107.
3. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002: 359: 1121-2.
4. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002: 359: 727-32.
5. Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001: 23: 1603-14.
6. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004: 101: 4180-5.
7. Daly AK, Donaldson PT, Bhatnagar P et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009: 41: 816-9.
8. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996: 271: 324-8.
9. Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996: 2: 405-11.
10. Chessman D, Kostenko L, Lethborg T et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008: 28: 822-32.
11. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008: 358: 568-79.
12. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003: 8: 36-41.
13. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002: 16: 2223-5.
14. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007: 21: 2533-4.
15. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007: 45: 1-3.
16. Barber LD, Percival L, Arnett KL, Gumperz JE, Chen L, Parham P. Polymorphism in the alpha 1 helix of the HLA-B heavy chain can have an overriding influence on peptide-binding specificity. J Immunol 1997: 158: 1660-9.
17. Clements CS, Kjer-Nielsen L, MacDonald WA et al. The production, purification and crystallization of a soluble heterodimeric form of a highly selected T-cell receptor in its unliganded and liganded state. Acta Crystallogr D Biol Crystallogr 2002: 58: 2131-4.
18. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975: 256: 495-7.
19. Goding J. Monoclonal Antibodies: Principles and Practice, 3rd edn. San Diego Academic Press, Harcourt Brace and Company, 1993.
20. Colombo MB, Haworth SE, Poli F et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 2007: 72: 465-71.
21. Rosenberg JC, Berri R, Jackowski M, Levis D, Nehlsen-Cannarella S, Oh H. Multi-array antibody screening in detecting antibodies to mismatched HLA in patients awaiting a second transplant. Transplant Proc 2006: 38: 3393-5.
22. Robinson J, Marsh SG. The IMGT/HLA sequence database. Rev Immunogenet.
23. Levering WH, Sintnicolaas K, Wind H, Hooijkaas H, Gratama JW. Flow cytometric screening for the HLA-B27 antigen on peripheral blood lymphocytes. Curr Protoc Cytom 2005 (Chapter 6: Unit 6.22).
24. Levering WH, Wind H, Sintnicolaas K, Hooijkaas H, Gratama JW. Flow cytometric HLA-B27 screening: cross-reactivity patterns of commercially available anti-HLA-B27 monoclonal antibodies with other HLA-B antigens. Cytometry B Clin Cytom 2003: 54: 28-38.
25. Marsh SGE, Parham P, Barber LD. The HLA Facts Book. London: Academic Press, 2000: 49.
26. McMichael AJ, Parham P, Rust N, Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol 1980: 1: 121-9.
27. Ways JP, Rothbard JB, Parham P. Amino acid residues 56 to 69 of HLA-A2 specify an antigenic determinant shared by HLA-A2 and HLA-B17. J Immunol 1986: 137: 217-22.